For Moderna's flu vaccine program, how should we weigh focusing on annual strain updates versus pursuing a universal flu vaccine?

Introduction

The trade-off between focusing on annual strain updates versus pursuing a universal flu vaccine for Moderna's flu vaccine program presents a critical strategic decision. This scenario involves balancing short-term effectiveness with long-term innovation in vaccine development. I'll analyze this trade-off by examining the product landscape, stakeholder impacts, and potential outcomes to provide a comprehensive recommendation.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking Moderna's current flu vaccine program might be primarily focused on annual updates. Could you confirm if they have an existing universal flu vaccine research program, and if so, at what stage?

Why it matters: Helps understand the starting point and resources already allocated. Expected answer: Early-stage universal vaccine research exists but isn't the primary focus. Impact on approach: Would influence resource allocation and timeline considerations.

• Business Context: Based on the competitive landscape, I assume annual strain updates are currently the main revenue driver. Can you share how significant flu vaccines are to Moderna's overall revenue?

Why it matters: Helps prioritize the trade-off against business objectives. Expected answer: Flu vaccines contribute 15-20% of annual revenue. Impact on approach: Higher percentage would favor maintaining focus on annual updates.

• User Impact: Considering patient needs, I'm curious about the effectiveness of current annual vaccines. What's the average efficacy rate, and how does it vary year to year?

Why it matters: Informs the potential value of a universal vaccine. Expected answer: Efficacy ranges from 40-60%, varying significantly each year. Impact on approach: Lower or highly variable efficacy would strengthen the case for universal vaccine development.

• Technical: Given the complexity of universal vaccine development, I'm wondering about the current technical feasibility. How close is the scientific community to developing a viable universal flu vaccine?

Why it matters: Affects the timeline and resource investment required. Expected answer: Promising research exists, but significant challenges remain. Impact on approach: Higher feasibility would justify more resources towards universal vaccine development.

• Resource: Considering the potential long-term investment, I'm curious about Moderna's R&D budget allocation. What percentage is currently dedicated to flu vaccine research?

Why it matters: Indicates capacity for pursuing universal vaccine development. Expected answer: 10-15% of R&D budget allocated to flu vaccine research. Impact on approach: Higher allocation would suggest more flexibility in pursuing universal vaccine development.